Description
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular Biology(TM) format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future. 1. Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review Ingrid Sassoon and Vronique Blanc 2. Antibody-Drug Conjugate Target Selection: Critical Factors Neil H. Bander 3. Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization Jay Harper, Shenlan Mao, Patrick Strout, and Adeela Kamal 4. Antibody-Drug Conjugate Payloads Jan Anderl, Heinz Faulstich, Torsten Hechler and Michael Kulke 5. Linker Technologies for Antibody-Drug Conjugates Birte Nolting 6. In Vivo Testing of Drug-Linker Stability Pierre-Yves Abecassis and Cline Amara 7. Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates Kedan Lin, Jay Tibbitts, and Ben-Quan Shen 8. Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment Miriam I. Hensgen and Bernhard Stump 9. Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting James E. Stefano, Michelle Busch, Lihui Hou, Anna Park, and Diego A. Gianolio 10. Protocols for Lysine Conjugation Marie-Priscille Brun and Laurence Gauzy-Lazo 11. Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers Sunil Bhakta, Helga Raab, and Jagath R. Junutula 12. Enzymatic Antibody Modification by Bacterial Transglutaminase Patrick Dennler, Roger Schibli, and Eliane Fischer 13. Formulation Development of Antibody-Drug Conjugates William J. Galush and Aditya A. Wakankar 14. Conjugation Process Development and Scale-Up Bernhard Stump and Jessica Steinmann 15. Methods for Conjugating Antibodies to Nanocarriers Anil Wagh and Benedict Law 16. Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy Yan Chen 17. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography Jun Ouyang 18. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS Louisette Basa 19. Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF Joyce Lin and Alexandru C. Lazar 20. Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs) Weibing Ding
